Comprehensive medication guide to Insulin Glargine-Yfgn including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$35/month copay for most insured patients; Medicare Part D IRA cap of $35/month applies to covered insulin glargine products. Commercial insurance coverage varies — some plans now require prior authorization or step therapy following the December 2025 Semglee discontinuation.
Estimated Cash Pricing
$45 for a box of 5 pens (Civica Rx/CalRx, launched Jan 2026 — lowest list price long-acting insulin in the US); as low as $20–$74 per pen with GoodRx or SingleCare coupons for generic insulin glargine-yfgn at participating pharmacies.
Medfinder Findability Score
45/100
On this page
Insulin glargine-yfgn is a long-acting biosimilar insulin analog used to control blood sugar in adults and children (ages 6+) with Type 1 diabetes, and in adults with Type 2 diabetes. It was originally marketed as Semglee by Biocon Biologics/Viatris and approved by the FDA on July 28, 2021 as the first interchangeable biosimilar insulin in US history.
The Semglee brand was discontinued on December 31, 2025. As of January 2026, unbranded insulin glargine-yfgn is available from Civica Rx at $45 for a box of five pens — the lowest list price for any long-acting insulin in the US. Generic versions from other manufacturers (Winthrop) also remain available.
Insulin glargine-yfgn is FDA-designated as interchangeable with Lantus (insulin glargine), meaning pharmacists can substitute one for the other at the point of dispensing without prescriber intervention — similar to how generic drugs substitute for brand-name drugs.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Insulin glargine-yfgn is a long-acting insulin analog engineered to provide a steady, peakless level of insulin over approximately 24 hours. It differs from human insulin in two key ways: the amino acid at position A21 (asparagine) is replaced by glycine, and two arginine amino acids are added to the C-terminus of the B-chain.
The solution in the vial or pen is acidic (pH ~4). When injected under the skin, it encounters the neutral pH of body tissue (~7.4) and precipitates, forming a slow-release depot. From this depot, small amounts of insulin are released into the bloodstream over 24 hours — mimicking the basal insulin your pancreas would normally produce continuously.
Once in the bloodstream, insulin glargine-yfgn binds to insulin receptors on muscle, fat, and liver cells. This stimulates glucose uptake by cells for energy, suppresses the liver's glucose output, inhibits fat breakdown, and promotes protein synthesis — restoring the metabolic balance disrupted by diabetes.
100 units/mL — prefilled pen (3 mL)
Single-patient-use pen; dials in 1-unit increments. Needles not included.
100 units/mL — vial (10 mL)
Multiple-dose vial for use with insulin syringes.
Insulin glargine-yfgn has a findability score of 45 out of 100, reflecting significant access challenges in 2026. The Semglee brand was discontinued December 31, 2025 by Biocon Biologics, triggering a market-wide transition. While unbranded insulin glargine-yfgn remains available from Civica Rx (launched January 2026 at $45/5 pens) and Winthrop, not all pharmacies have established supplier relationships for the new versions.
Supply varies significantly by region and pharmacy type. Large chain pharmacies (CVS, Walgreens, Walmart) are more likely to carry it than smaller independent pharmacies. If insulin glargine-yfgn is unavailable, Lantus is interchangeable and can be substituted without a new prescription. ASHP lists an active shortage for insulin glargine recombinant products as of mid-2026.
If you're having difficulty locating insulin glargine-yfgn, medfinder contacts pharmacies near you to check which ones have it in stock and texts you the results — saving you from hours on hold.
Insulin glargine-yfgn is not a controlled substance and has no DEA scheduling. Any licensed prescriber in the United States can write a prescription for it without special certification or registration. The following provider types routinely prescribe this medication:
Endocrinologists — diabetes and hormone specialists; preferred for complex Type 1 management
Primary care physicians (PCPs) — family medicine and internal medicine physicians; routinely manage Type 2 diabetes with insulin
Nurse practitioners (NPs) and Physician assistants (PAs) — can prescribe in most states; check state-specific scope of practice
Pediatricians — can prescribe for children ages 6+ with Type 1 diabetes; complex cases may be co-managed with pediatric endocrinologists
Telehealth providers can also prescribe insulin glargine-yfgn for established diabetes patients in most states, typically offering appointments within 24–48 hours. Platforms including Teladoc Health, MDLive, and diabetes-specialized services like Virta Health are commonly used for insulin management via telemedicine.
No. Insulin glargine-yfgn is not a controlled substance and is not scheduled by the DEA. Any licensed healthcare provider — including primary care physicians, nurse practitioners, physician assistants, endocrinologists, and telehealth providers — can prescribe it without special DEA registration or prescribing restrictions.
Insulin glargine-yfgn is a prescription medication in the United States and requires a valid prescription for dispensing. It cannot be refilled at a pharmacy counter without a prescription. However, some states have emergency insulin dispensing laws that allow pharmacists to dispense insulin without a prescription in urgent situations — check your state's laws with your pharmacist.
The most common and clinically significant side effect is hypoglycemia (low blood sugar), which is listed as a boxed warning in the FDA prescribing information. Common side effects include:
Hypoglycemia — shaking, sweating, confusion, rapid heartbeat, dizziness
Injection site reactions — redness, pain, itching, bruising
Lipodystrophy — skin thickening or scarring at injection sites
Weight gain
Serious side effects requiring emergency care:
Severe hypoglycemia with seizure or unconsciousness — call 911, use glucagon emergency kit
Hypokalemia (dangerously low potassium) — muscle cramps, irregular heartbeat, weakness
Severe allergic reaction (anaphylaxis) — rash, difficulty breathing, swelling of throat — call 911
Heart failure (when combined with PPAR-gamma agonists like pioglitazone)
Know what you need? Skip the search.
Lantus (insulin glargine)
The reference product for insulin glargine-yfgn and its FDA-designated interchangeable substitute. Same mechanism and clinical effect. Pharmacists can substitute without a new prescription. Sanofi Valyou program: $35/month.
Basaglar (insulin glargine)
Eli Lilly's long-acting insulin glargine product. Clinically equivalent to Lantus and insulin glargine-yfgn but not interchangeable — requires a new prescription. $35/month via Eli Lilly program.
Rezvoglar (insulin glargine-aglr)
Eli Lilly's biosimilar insulin glargine, approved December 2021. Requires a new prescription. Growing availability.
Toujeo (insulin glargine U-300)
Concentrated insulin glargine at 300 units/mL from Sanofi. Longer duration, less nocturnal hypoglycemia risk. Requires dose adjustment (start at 80% of U-100 dose) and new prescription.
Prefer Insulin Glargine-Yfgn? We can find it.
Corticosteroids (prednisone, dexamethasone)
majorCan raise blood sugar significantly, requiring higher insulin doses. Monitor closely when starting, adjusting, or stopping steroid therapy.
Beta-blockers (atenolol, metoprolol, propranolol)
moderateCan mask hypoglycemia warning signs (rapid heartbeat, tremors). Sweating is usually not masked. Rely on blood glucose monitoring rather than symptoms.
Other antidiabetic agents (sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors)
majorCombined use with insulin can increase risk of hypoglycemia. Dose adjustments and more frequent monitoring may be needed.
ACE inhibitors and ARBs (lisinopril, losartan)
moderateCan enhance insulin sensitivity and increase hypoglycemia risk. Monitor blood glucose when starting or adjusting dose.
Thiazolidinediones (pioglitazone)
majorCan cause fluid retention and worsen heart failure when combined with insulin. Report sudden weight gain, swelling, or shortness of breath immediately.
Alcohol
moderateCan cause unpredictable hypoglycemia, especially on an empty stomach. Can also mask hypoglycemia symptoms. Use with caution; eat when drinking.
Insulin glargine-yfgn holds a unique place in diabetes care history as the first FDA-designated interchangeable biosimilar insulin — a milestone that opened the door to more affordable, competitive basal insulin options for millions of Americans. While the Semglee brand has been discontinued, the drug continues to be available in 2026 through Civica Rx (at the lowest list price for any long-acting insulin) and other manufacturers.
For patients navigating the 2026 supply transition, the most important things to know are: the unbranded drug is still available, Lantus is an interchangeable substitute that requires no new prescription, and multiple savings programs exist to keep your monthly insulin cost to $35 or less. Talk to your healthcare provider about which option is best for your situation.
If you're struggling to find insulin glargine-yfgn at your pharmacy, medfinder can help — we contact pharmacies in your area to check which ones have your prescription in stock and text you the results.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Insulin Glargine-Yfgn. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini